4.7 Review

Stroke-heart syndrome: clinical presentation and underlying mechanisms

期刊

LANCET NEUROLOGY
卷 17, 期 12, 页码 1109-1120

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(18)30336-3

关键词

-

资金

  1. Corona-Stiftung
  2. W L Gore Associates
  3. Pfizer Pharma
  4. Bristol-Myers Squibb
  5. Sanofi
  6. Vifor
  7. ZS Pharma
  8. Bayer
  9. German Research Foundation
  10. German Federal Ministry of Education and Research
  11. German Center for Neurodegenerative Diseases
  12. German Centre for Cardiovascular Research
  13. EU
  14. Corona Foundation
  15. Fondation Leducq

向作者/读者索取更多资源

Cardiac complications are a frequent medical problem during the first few days after an ischaemic stroke, and patients present with a broad range of symptoms including myocardial injury, cardiac dysfunction, and arrhythmia, with varying overlap between these three conditions. Evidence from clinical and neuroimaging studies and animal research suggests that these cardiac disturbances share the same underlying mechanisms. Although the exact cascade of events has yet to be elucidated, stroke-induced functional and structural alterations in the central autonomic network, with subsequent dysregulation of normal neural cardiac control, are the assumed pathophysiology. This dysregulation can promote myocardial necrosis, microvascular dysfunction, coronary demand ischaemia, and arrhythmogenesis. These stroke-associated cardiac alterations can be summarised as a distinct so-called stroke-heart syndrome. Independent cohort studies have shown a strong association between this syndrome and unfavourable short-term prognosis; however, long-term consequences, including secondary cardiac events and death, are less well described and specific therapeutic targets are scarce. An integrated view of stroke-heart syndrome will offer opportunities to expedite research and inform clinical decision making.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据